Breakthrough Study Highlights Promising Peptide Therapy Against Aggressive Brain Cancer
Virginia Tech scientists have developed a promising peptide therapy targeting glioblastoma stem cells that could reduce tumor recurrence and improve treatment outcomes.
Scientists from Virginia Tech's Fralin Biomedical Research Institute have made a significant advancement in the fight against glioblastoma, one of the most deadly and treatment-resistant brain tumors. They developed a lab-designed peptide, JM2, which shows potential in slowing tumor recurrence by targeting glioblastoma stem cells that often survive conventional treatments like chemotherapy and radiation.
Published in Cell Death and Disease, the research uncovers a novel mechanism involving connexin 43, a protein critical for cell communication. Glioblastoma stem cells utilize connexin 43 to interact with microtubules, helping them to survive and reinitiate tumor growth after treatment. Using super-resolution microscopy, researchers visualized this interaction at the nanoscale, revealing that disrupting connexin 43’s association with microtubules can selectively kill these harmful cells.
The peptide JM2, derived from connexin 43, mimics its microtubule-interacting domain and effectively disrupts this interaction. When tested in laboratory cell cultures and animal models, JM2 significantly slowed tumor growth and hindered the maintenance of treatment-resistant cancer cells, demonstrating its promise as a targeted therapy.
This breakthrough is part of a broader effort to develop combination therapies that incorporate JM2 with existing treatments to enhance patient survival and reduce recurrence. Ongoing research aims to optimize delivery methods, including biodegradable nanoparticles and viral vectors, to ensure precise targeting of glioblastoma cells.
Developed with collaboration between Virginia Tech and Carilion Clinic, the researchers envision JM2 as a first step toward innovative peptide-based strategies for combating glioblastoma. Though further studies are necessary to ensure safety and efficacy in humans, these findings ignite hope for more effective treatments for patients facing this devastating disease.
For more information, see the full study in Cell Death and Disease and related updates from Virginia Tech.
Source: https://medicalxpress.com/news/2025-05-scientists-peptide-drug-combat-deadly.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Most Americans Recognize Plasma Donation as a Life-Saving Practice But Participation Remains Low
A recent survey uncovers that while most Americans recognize the life-saving potential of plasma donation, actual participation remains low, highlighting the need for increased awareness and education during International Plasma Awareness Week.
U.S. Commits to Purchasing 2 Million Doses of HIV Prevention Medication for Low-Income Nations
The U.S. will purchase 2 million doses of a groundbreaking HIV prevention shot to aid low-income countries, aiming to reduce new infections significantly by 2028 through international collaboration and innovative treatment solutions.
New Target Identified in Neurodegenerative Disease: The Role of GADD45G Protein
UT Southwestern Medical Center researchers have identified GADD45G as a master regulator of reactive gliosis, a key process in neurodegenerative diseases. Modulating this protein could pave the way for new therapies for conditions like Alzheimer's and Parkinson's.
The Impact of Losing Health Insurance on Your Primary Doctor and Overall Well-Being
Losing health insurance can break vital links to your primary care provider, leading to worse health outcomes and higher healthcare costs. Maintaining coverage ensures preventive care, early diagnosis, and ongoing health management.